Several different approaches were used to test for MET dysregulation, including overexpression as IHC2+ or IHC3+ in ≥50% of the tumor cells by IHC and MET GCN ≥ 5 or MET/CEP7 ratio ≥ 2.0 by FISH. This evidence concerns the gene MET and neoplasm.